• Home
  •  / Champions Oncology

Champions Oncology

OverviewSuggest Edit

Champions Oncology develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides Personalized Oncology Solutions that assist physicians in developing personalized treatment options for cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services.

TypePublic
Founded2007
HQHackensack, USMap
Websitechampionsoncology.com
Employee Ratings3More
Culture scoreA-More
View Jobs (13)

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2019)115(+25%)
Job Openings13
Revenue (FY, 2019)$27.1 M(+34%)
Share Price (Mar 2020)$6.6 (+2%)

Key People/Management at Champions Oncology

Ronnie Morris

Ronnie Morris

Chief Executive Officer
Philip Breitfeld

Philip Breitfeld

Chief Strategy and Innovation Officer
David Miller

David Miller

Chief Financial Officer
Michael Ritchie

Michael Ritchie

Vice President of Business Development
Maria Mancini

Maria Mancini

Vice President, Pharmacology
David Deornellis

David Deornellis

Vice President, Global Laboratory Operations
Show more

Champions Oncology Office Locations

Champions Oncology has offices in Hackensack, Rockville and London
Hackensack, US (HQ)
1 University Plaza Dr #307
Rockville, US
1330 Piccard Dr #025
London, GB
2 Royal College St
Show all (3)

Champions Oncology Financials and Metrics

Champions Oncology Revenue

Champions Oncology's revenue was reported to be $27.07 m in FY, 2019
USD

Revenue (Q3, 2020)

9.0m

Gross profit (Q3, 2020)

4.7m

Gross profit margin (Q3, 2020), %

52%

Net income (Q3, 2020)

407.0k

EBIT (Q3, 2020)

433.0k

Market capitalization (27-Mar-2020)

78.9m

Closing stock price (27-Mar-2020)

6.6

Cash (31-Jan-2020)

3.3m

EV

79.4m
Champions Oncology's current market capitalization is $78.9 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.1m8.3m11.6m8.9m11.2m15.4m20.2m27.1m

Revenue growth, %

(23%)26%

Sales and marketing expense

2.9m2.7m3.2m4.3m3.4m3.3m2.6m3.1m

General and administrative expense

5.5m4.6m6.1m5.3m5.2m5.0m4.1m4.7m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.6m1.7m2.4m2.1m1.5m2.9m3.0m2.4m3.7m1.9m1.9m1.8m2.8m3.0m2.6m3.7m4.5m3.6m5.0m5.2m5.1m6.2m6.7m6.4m6.7m7.6m9.0m

Cost of goods sold

3.1m3.5m3.4m3.8m3.9m4.3m

Gross profit

3.1m3.2m3.0m3.0m3.7m4.7m

Gross profit Margin, %

50%48%47%44%49%52%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.8m9.6m5.9m9.4m3.3m856.0k3.2m

Accounts Receivable

584.0k500.0k1.3m1.1m1.3m2.3m3.9m4.4m

Prepaid Expenses

205.0k315.0k383.0k346.0k300.0k287.0k308.0k

Inventories

443.0k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

8.8m7.1m6.5m2.9m2.2m10.8m7.4m7.6m5.8m3.1m575.0k182.0k6.8m4.2m3.3m4.5m4.3m3.5m400.0k700.0k1.1m1.0m2.0m3.3m2.2m2.8m3.3m

Accounts Receivable

1.2m832.0k497.0k639.0k627.0k642.0k1.8m1.5m3.1m925.0k1.1m1.1m1.5m1.9m2.1m1.6m1.9m2.0m2.7m2.6m2.9m3.8m4.7m3.9m3.9m3.9m4.5m

Prepaid Expenses

341.0k328.0k110.0k208.0k95.0k300.0k255.0k219.0k281.0k456.0k393.0k258.0k366.0k295.0k414.0k349.0k445.0k541.0k360.0k303.0k185.0k246.0k262.0k298.0k256.0k363.0k355.0k

Current Assets

10.9m8.8m7.6m3.8m2.9m11.7m9.4m9.3m9.2m4.4m2.1m1.5m8.6m6.3m5.8m6.4m6.7m6.1m3.5m3.5m4.2m5.0m6.9m7.5m6.3m7.1m8.1m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(8.7m)(6.3m)(7.4m)(13.1m)(10.4m)(1.5m)128.0k

Depreciation and Amortization

105.0k203.0k213.0k214.0k156.0k168.0k360.0k606.0k

Accounts Payable

96.0k(472.0k)(223.0k)433.0k482.0k(43.0k)301.0k653.0k

Cash From Operating Activities

(5.2m)(4.3m)(3.4m)(9.6m)(6.5m)(2.8m)(1.2m)1.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.0m)(4.4m)(6.1m)(1.3m)(3.3m)(4.3m)(2.2m)(4.6m)(5.1m)(3.5m)(6.7m)(9.5m)(2.9m)(5.5m)(7.9m)(2.5m)(3.1m)(4.5m)(674.2k)(768.5k)(844.0k)482.0k750.0k381.0k(641.0k)(334.0k)72.0k

Depreciation and Amortization

29.0k49.0k65.0k54.0k103.0k153.0k50.0k102.0k158.0k56.0k110.0k166.0k37.0k76.0k114.0k45.0k87.0k127.0k42.0k132.0k253.0k118.0k269.0k433.0k182.0k360.0k579.0k

Accounts Payable

(82.0k)(286.0k)43.0k(385.0k)(467.0k)(574.0k)(227.0k)(220.0k)(266.0k)347.0k651.0k381.0k22.0k(76.0k)101.0k(387.0k)(744.0k)(572.0k)(120.0k)(303.0k)124.0k(43.0k)(141.0k)(46.0k)(82.0k)(341.0k)(913.0k)

Cash From Operating Activities

(1.5m)(3.3m)(3.7m)(1.8m)(2.6m)(3.1m)(2.1m)(1.9m)(3.6m)(2.8m)(5.2m)(7.6m)(2.5m)(5.1m)(5.9m)(2.4m)(2.6m)(3.2m)(1.9m)(1.7m)(1.2m)336.0k400.0k1.6m(279.0k)81.0k360.0k
show all
USDY, 2020

EV/EBIT

183.5 x

EV/CFO

220.7 x

Financial Leverage

4.7 x
Show all financial metrics

Champions Oncology Online and Social Media Presence

Champions Oncology's Trends

Embed Graph

Champions Oncology Company Culture

  • Overall Culture

    A-

    86/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Champions Oncology News and Updates

December 10, 2018

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018

HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and...
September 13, 2018

Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first...
September 13, 2018

Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York

HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at...
July 26, 2018

Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

HACKENSACK, N.J., July 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter...

Champions Oncology Blogs

January 29, 2020

The Children’s Cancer Therapy Development Institute is Collaborating with Champions Oncology and Jackson Laboratory to provide RACEact/PREA Pediatric Cancer Study Plan Services

The Children’s Cancer Therapy Development Institute is collaborating with Champions Oncology and The Jackson Laboratory to provide RACE Act/PREA pediatric cancer study plan services The Children’s Cancer Therapy Development Institute (cc-TDI), Champions Oncology, and The Jackson Laboratory offer rap…
November 15, 2019

Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-Based Phenotypic Assays for Preclinical Drug Development

Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-based Phenotypic Assays for Preclinical Drug Development Hackensack, NJ – November 13, 2019 – Champions Oncology (NASDAQ: CSBR), an end-to-end R&D Oncology solutions company announced today…
July 11, 2019

Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations

  HACKENSACK, NJ – May 30, 2019  –  Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the…
August 08, 2018

Champions Oncology Granted Full Accreditation by the AAALAC

Hackensack, NJ – August 8, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that its new facility in Rockville, MD has been granted Full Accreditation by …

 Champions Oncology Frequently Asked Questions

  • When was Champions Oncology founded?

    Champions Oncology was founded in 2007.

  • Who are Champions Oncology key executives?

    Champions Oncology's key executives are Ronnie Morris, Philip Breitfeld and David Miller.

  • How many employees does Champions Oncology have?

    Champions Oncology has 115 employees.

  • What is Champions Oncology revenue?

    Latest Champions Oncology annual revenue is $27.1 m.

  • What is Champions Oncology revenue per employee?

    Latest Champions Oncology revenue per employee is $235.4 k.

  • Who are Champions Oncology competitors?

    Competitors of Champions Oncology include Remedy Plan, Evaxion Biotech and Kleo.

  • Where is Champions Oncology headquarters?

    Champions Oncology headquarters is located at 1 University Plaza Dr #307, Hackensack.

  • Where are Champions Oncology offices?

    Champions Oncology has offices in Hackensack, Rockville and London.

  • How many offices does Champions Oncology have?

    Champions Oncology has 3 offices.